Orchard Therapeutics PLC - ADR - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ORTX Nasdaq 2836 https://www.orchard-tx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Orchard Therapeutics PLC - ADR

Analyst Forecasts For Orchard Therapeutics plc (NASDAQ:ORTX) Are Surging Higher - Mar 16th, 2023 10:26 am
Orchard Therapeutics plc (NASDAQ:ORTX) Q4 2022 Earnings Call Transcript - Mar 13th, 2023 3:51 pm
Institutions own 23% of Orchard Therapeutics plc (NASDAQ:ORTX) shares but retail investors control 34% of the company - Mar 11th, 2023 2:06 pm
Orchard Therapeutics Completes ADS Ratio Change - Mar 10th, 2023 3:00 pm
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results - Mar 6th, 2023 11:05 am
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million - Mar 6th, 2023 11:00 am
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023 - Mar 3rd, 2023 12:00 pm
11 High Growth UK Stocks to Buy - Mar 1st, 2023 11:01 am
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden - Feb 27th, 2023 12:00 pm
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™ - Feb 24th, 2023 12:00 pm
Orchard Therapeutics Announces Proposed ADS Ratio Change - Feb 10th, 2023 12:00 pm
Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium - Feb 8th, 2023 12:00 pm
Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones - Jan 9th, 2023 12:00 pm
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH - Jan 5th, 2023 12:00 pm
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA - Dec 12th, 2022 12:00 pm
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel) - Dec 1st, 2022 12:00 pm
Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights - Nov 14th, 2022 12:00 pm
Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022 - Nov 8th, 2022 12:00 pm
Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results - Nov 7th, 2022 12:00 pm
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022 - Nov 3rd, 2022 1:05 pm